Nihal M. El-Mahdy El-Sayyad , Alia Badawi , Mohammed Effat Abdullah , Nevine Shawky Abdelmalak
{"title":"结合自乳化给药系统和液相概念的来氟米特溶解增强","authors":"Nihal M. El-Mahdy El-Sayyad , Alia Badawi , Mohammed Effat Abdullah , Nevine Shawky Abdelmalak","doi":"10.1016/j.bfopcu.2017.02.001","DOIUrl":null,"url":null,"abstract":"<div><p>The objective of this study is to enhance the dissolution properties of leflunomide, a class BCS-II drug by incorporating the self emulsifying (SE) form of the drug onto liquisolid systems in the form of tablets. Different formulae were prepared by dissolving leflunomide in PEG300 then forming SE systems using tween 80 as surfactant and either sesame oil and paraffin oil then adsorbing on powder excipients to form SE liquisolid powders. The prepared powders showed adequate flowability. The drug and excipients showed compatibility by analysis with DSC, XRD and FTIR. After compression, all tablets showed adequate weight variation, friability and disintegration time with disintegration time ranging between 8.45<!--> <!-->±<!--> <!-->0.16<!--> <!-->min and 10.7<!--> <!-->±<!--> <!-->0.29<!--> <!-->min. All liquisolid tablets exhibited higher in vitro dissolution in distilled water compared to physical mixture and the commercial tablets (Arthfree®) with formula containing sesame oil and highest amount of solvent (TS04) exhibiting the highest dissolution profile and it did not change by the change in the pH of the dissolution medium. The tablets showed stability during a 6<!--> <!-->months accelerated stability study according to appearance, drug content, disintegration time and dissolution profile. Thus it can be concluded that combining self emulsifying drug delivery technique and liquisolid technology can be a promising tool to enhance the dissolution profile of leflunomide in vitro.</p></div>","PeriodicalId":9369,"journal":{"name":"Bulletin of Faculty of Pharmacy, Cairo University","volume":"55 1","pages":"Pages 53-62"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bfopcu.2017.02.001","citationCount":"21","resultStr":"{\"title\":\"Dissolution enhancement of leflunomide incorporating self emulsifying drug delivery systems and liquisolid concepts\",\"authors\":\"Nihal M. El-Mahdy El-Sayyad , Alia Badawi , Mohammed Effat Abdullah , Nevine Shawky Abdelmalak\",\"doi\":\"10.1016/j.bfopcu.2017.02.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The objective of this study is to enhance the dissolution properties of leflunomide, a class BCS-II drug by incorporating the self emulsifying (SE) form of the drug onto liquisolid systems in the form of tablets. Different formulae were prepared by dissolving leflunomide in PEG300 then forming SE systems using tween 80 as surfactant and either sesame oil and paraffin oil then adsorbing on powder excipients to form SE liquisolid powders. The prepared powders showed adequate flowability. The drug and excipients showed compatibility by analysis with DSC, XRD and FTIR. After compression, all tablets showed adequate weight variation, friability and disintegration time with disintegration time ranging between 8.45<!--> <!-->±<!--> <!-->0.16<!--> <!-->min and 10.7<!--> <!-->±<!--> <!-->0.29<!--> <!-->min. All liquisolid tablets exhibited higher in vitro dissolution in distilled water compared to physical mixture and the commercial tablets (Arthfree®) with formula containing sesame oil and highest amount of solvent (TS04) exhibiting the highest dissolution profile and it did not change by the change in the pH of the dissolution medium. The tablets showed stability during a 6<!--> <!-->months accelerated stability study according to appearance, drug content, disintegration time and dissolution profile. Thus it can be concluded that combining self emulsifying drug delivery technique and liquisolid technology can be a promising tool to enhance the dissolution profile of leflunomide in vitro.</p></div>\",\"PeriodicalId\":9369,\"journal\":{\"name\":\"Bulletin of Faculty of Pharmacy, Cairo University\",\"volume\":\"55 1\",\"pages\":\"Pages 53-62\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.bfopcu.2017.02.001\",\"citationCount\":\"21\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Faculty of Pharmacy, Cairo University\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1110093117300066\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Faculty of Pharmacy, Cairo University","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1110093117300066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 21
摘要
本研究的目的是通过将BCS-II类药物来氟米特的自乳化(SE)形式纳入片剂的液固体系,提高其溶出性能。将来氟米特溶于PEG300中,以80为表面活性剂,芝麻油和石蜡油分别吸附在粉末辅料上形成SE液体固体粉末,制备不同配方的SE。制备的粉末具有良好的流动性。DSC、XRD、FTIR等分析表明,药物与辅料配伍性良好。压缩后,所有药片都显示出足够的重量变化。崩解时间在8.45±0.16 min ~ 10.7±0.29 min之间。所有液体固体片剂在蒸馏水中的体外溶出度均高于物理混合物,而以香油和最高溶剂量(TS04)为配方的市售片剂(Arthfree®)的体外溶出度最高,且不随溶出介质pH的变化而变化。在6个月的加速稳定性研究中,该片剂的外观、药物含量、崩解时间和溶出度均表现出稳定性。综上所述,自乳化给药技术与液固相结合是提高来氟米特体外溶出度的有效手段。
Dissolution enhancement of leflunomide incorporating self emulsifying drug delivery systems and liquisolid concepts
The objective of this study is to enhance the dissolution properties of leflunomide, a class BCS-II drug by incorporating the self emulsifying (SE) form of the drug onto liquisolid systems in the form of tablets. Different formulae were prepared by dissolving leflunomide in PEG300 then forming SE systems using tween 80 as surfactant and either sesame oil and paraffin oil then adsorbing on powder excipients to form SE liquisolid powders. The prepared powders showed adequate flowability. The drug and excipients showed compatibility by analysis with DSC, XRD and FTIR. After compression, all tablets showed adequate weight variation, friability and disintegration time with disintegration time ranging between 8.45 ± 0.16 min and 10.7 ± 0.29 min. All liquisolid tablets exhibited higher in vitro dissolution in distilled water compared to physical mixture and the commercial tablets (Arthfree®) with formula containing sesame oil and highest amount of solvent (TS04) exhibiting the highest dissolution profile and it did not change by the change in the pH of the dissolution medium. The tablets showed stability during a 6 months accelerated stability study according to appearance, drug content, disintegration time and dissolution profile. Thus it can be concluded that combining self emulsifying drug delivery technique and liquisolid technology can be a promising tool to enhance the dissolution profile of leflunomide in vitro.